444 related articles for article (PubMed ID: 31248849)
61. Stereotactic ablative radiotherapy (SABR) as primary, adjuvant, consolidation and re-treatment option in pancreatic cancer: scope for dose escalation and lessons for toxicity.
Goldsmith C; Plowman PN; Green MM; Dale RG; Price PM
Radiat Oncol; 2018 Oct; 13(1):204. PubMed ID: 30340643
[TBL] [Abstract][Full Text] [Related]
62. Feasible Optimization of Stereotactic Ablative Radiotherapy Dose by Tumor Size for Stage I Non-small-cell Lung Cancer.
Lee S; Song SY; Kim SS; Choi W; Je HU; Back GM; Cho B; Jeong SY; Choi EK
Clin Lung Cancer; 2018 Mar; 19(2):e253-e261. PubMed ID: 29196082
[TBL] [Abstract][Full Text] [Related]
63. Stereotactic Ablative Radiation (SAbR) for Oligometastatic RCC.
All S; Garant A; Hannan R
Semin Radiat Oncol; 2021 Jul; 31(3):227-234. PubMed ID: 34090649
[TBL] [Abstract][Full Text] [Related]
64. Stereotactic body radiotherapy (SBRT) for medically inoperable lung metastases-A pooled analysis of the German working group "stereotactic radiotherapy".
Rieber J; Streblow J; Uhlmann L; Flentje M; Duma M; Ernst I; Blanck O; Wittig A; Boda-Heggemann J; Krempien R; Lohaus F; Klass ND; Eble MJ; Imhoff D; Kahl H; Petersen C; Gerum S; Henkenberens C; Adebahr S; Hass P; Schrade E; Wendt TG; Hildebrandt G; Andratschke N; Sterzing F; Guckenberger M
Lung Cancer; 2016 Jul; 97():51-8. PubMed ID: 27237028
[TBL] [Abstract][Full Text] [Related]
65. Stereotactic Ablative Radiotherapy (SABR) in Patients with Medically Inoperable Peripheral Early Stage Lung Cancer: Outcomes for the First UK SABR Cohort.
Murray L; Ramasamy S; Lilley J; Snee M; Clarke K; Musunuru HB; Needham A; Turner R; Sangha V; Flatley M; Franks K
Clin Oncol (R Coll Radiol); 2016 Jan; 28(1):4-12. PubMed ID: 26474546
[TBL] [Abstract][Full Text] [Related]
66. Breaking barriers: Stereotactic ablative proton and photon radiation therapy for renal cell carcinoma with extensive metastases: A case report.
Ma MW; Wang ZS; Li HZ; Gao XS; Liu C; Ren XY; Zhang WL; Yang KW
Med Dosim; 2024 Spring; 49(1):41-45. PubMed ID: 37563017
[TBL] [Abstract][Full Text] [Related]
67. Radiation therapy options in kidney cancer.
Zaorsky NG; Louie AV; Siva S
Curr Opin Support Palliat Care; 2023 Dec; 17(4):308-314. PubMed ID: 37877449
[TBL] [Abstract][Full Text] [Related]
68. Stereotactic ablative radiotherapy for primary renal cell carcinoma.
Yang DX; Kwon YS; Timmerman R; Hannan R
Clin Transl Radiat Oncol; 2024 Jan; 44():100705. PubMed ID: 38073715
[TBL] [Abstract][Full Text] [Related]
69. Stereotactic body radiation therapy for melanoma and renal cell carcinoma: impact of single fraction equivalent dose on local control.
Stinauer MA; Kavanagh BD; Schefter TE; Gonzalez R; Flaig T; Lewis K; Robinson W; Chidel M; Glode M; Raben D
Radiat Oncol; 2011 Apr; 6():34. PubMed ID: 21477295
[TBL] [Abstract][Full Text] [Related]
70. Stereotactic Radiotherapy and Short-course Pembrolizumab for Oligometastatic Renal Cell Carcinoma-The RAPPORT Trial.
Siva S; Bressel M; Wood ST; Shaw MG; Loi S; Sandhu SK; Tran B; A Azad A; Lewin JH; Cuff KE; Liu HY; Moon D; Goad J; Wong LM; LimJoon M; Mooi J; Chander S; Murphy DG; Lawrentschuk N; Pryor D
Eur Urol; 2022 Apr; 81(4):364-372. PubMed ID: 34953600
[TBL] [Abstract][Full Text] [Related]
71. Dose-response of localized renal cell carcinoma after stereotactic body radiation therapy: A meta-analysis.
Huang RS; Chow R; Chopade P; Mihalache A; Hasan A; Boldt G; Glicksman R; Simone CB; Lock M; Raman S
Radiother Oncol; 2024 May; 194():110216. PubMed ID: 38462092
[TBL] [Abstract][Full Text] [Related]
72. Is radiofrequency ablation more effective than stereotactic ablative radiotherapy in patients with early stage medically inoperable non-small cell lung cancer?
Bilal H; Mahmood S; Rajashanker B; Shah R
Interact Cardiovasc Thorac Surg; 2012 Aug; 15(2):258-65. PubMed ID: 22581864
[TBL] [Abstract][Full Text] [Related]
73. The emerging roles of stereotactic ablative radiotherapy for metastatic renal cell carcinoma.
Cheung P; Thibault I; Bjarnason GA
Curr Opin Support Palliat Care; 2014 Sep; 8(3):258-64. PubMed ID: 25090288
[TBL] [Abstract][Full Text] [Related]
74. A phase I dose-escalation trial of stereotactic ablative body radiotherapy for non-spine bone and lymph node metastases (DESTROY-trial).
Mercier C; Dirix P; Meijnders P; Vermeulen P; Van Laere S; Debois H; Huget P; Verellen D
Radiat Oncol; 2018 Aug; 13(1):152. PubMed ID: 30126440
[TBL] [Abstract][Full Text] [Related]
75. Stereotactic Body Radiotherapy for Renal Cell Carcinoma: Oncological and Renal Function Outcomes.
Glicksman RM; Cheung P; Korol R; Niglas M; Nusrat H; Erler D; Vesprini D; Swaminath A; Davidson M; Zhang L; Chu W
Clin Oncol (R Coll Radiol); 2023 Jan; 35(1):20-28. PubMed ID: 35948465
[TBL] [Abstract][Full Text] [Related]
76. The investigational role of cytoreductive stereotactic ablative radiation therapy (SABR) to the primary tumor in metastatic kidney cancer.
Ingrosso G; Lancia A; Festa E; Pisani AR; Bellavita R; Aristei C; Detti B
Expert Rev Anticancer Ther; 2024 Jul; 24(7):477-479. PubMed ID: 38682638
[No Abstract] [Full Text] [Related]
77. Factors affecting survival in 37 consecutive patients undergoing de novo stereotactic radiosurgery for contiguous sites of vertebral body metastasis from renal cell carcinoma.
Sellin JN; Reichardt W; Bishop AJ; Suki D; Rhines LD; Settle SH; Brown PD; Li J; Rao G; Chang EL; Tatsui CE
J Neurosurg Spine; 2015 Jan; 22(1):52-9. PubMed ID: 25360530
[TBL] [Abstract][Full Text] [Related]
78. Advances in radiotherapy in bone metastases in the context of new target therapies and ablative alternatives: A critical review.
Gouveia AG; Chan DCW; Hoskin PJ; Marta GN; Trippa F; Maranzano E; Chow E; Silva MF
Radiother Oncol; 2021 Oct; 163():55-67. PubMed ID: 34333087
[TBL] [Abstract][Full Text] [Related]
79. Use of Stereotactic Ablative Radiotherapy (SABR) in Non-Small Cell Lung Cancer Measuring More Than 5 cm.
Tekatli H; van 't Hof S; Nossent EJ; Dahele M; Verbakel WFAR; Slotman BJ; Senan S
J Thorac Oncol; 2017 Jun; 12(6):974-982. PubMed ID: 28286243
[TBL] [Abstract][Full Text] [Related]
80. Predictive factors for local control in primary and metastatic lung tumours after four to five fraction stereotactic ablative body radiotherapy: a single institution's comprehensive experience.
Thibault I; Poon I; Yeung L; Erler D; Kim A; Keller B; Lochray F; Jain S; Soliman H; Cheung P
Clin Oncol (R Coll Radiol); 2014 Nov; 26(11):713-9. PubMed ID: 25085765
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
